Skip to main content

Table 3 First-line drug resistance by study site and treatment history

From: The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance

Study site

Treatment history

First-line drug resistance

Total

DST profiles of resistant isolates

Pan susceptible

Any resistance

RMP mono

INH mono

SM mono

EMB mono

PDR

MDR

N

%

n

%

N

%

n

%

n

%

n

%

N

%

n

%

Burkina Faso

All

 

18

(67)

9

(33)

27

0

(0)

2

(7)

1

(4)

0

(0)

4

(15)

2

(7)

New

13

(65)

7

(35)

20

0

(0)

2

(10)

1

(5)

0

(0)

3

(15)

1

(5)

Retreatment

0

(0)

1

(100)

1

0

(0)

0

(0)

0

(0)

0

(0)

0

(0)

1

(100)

Unknown

5

(83)

1

(17)

6

0

(0)

0

(0)

0

(0)

0

(0)

1

(17)

0

(0)

The Gambia

All

 

80

(77)

24

(23)

104

1

(1)

4

(4)

6

(6)

0

(0)

1

(1)

12

(11)

New

7

(78)

2

(22)

9

0

(0)

1

(11)

1

(11)

0

(0)

0

(0)

0

(0)

Retreatment

73

(77)

22

(23)

95

1

(1)

3

(3)

5

(5)

0

(0)

1

(1)

12

(13)

Ghana

All

 

64

(50)

63

(50)

127

1

(0)

7

(5)

13

(10)

0

(0)

9

(7)

33

(26)

New

11

(73)

4

(27)

15

0

(0)

1

(7)

1

(7)

0

(0)

0

(0)

2

(13)

Retreatment

53

(47)

59

(53)

112

1

(1)

6

(5)

12

(11)

0

(0)

9

(8)

31

(28)

Guinea-Bissau

All

 

34

(77)

10

(23)

44

2

(4)

1

(2)

1

(2)

1

(2)

2

(5)

3

(7)

New

24

(75)

8

(25)

32

2

(6)

1

(3)

1

(3)

1

(3)

2

(6)

1

(3)

Retreatment

2

(50)

2

(50)

4

0

(0)

0

(0)

0

(0)

0

(0)

0

(0)

2

(50)

Unknown

8

(100)

0

(0)

8

0

(0)

0

(0)

0

(0)

0

(0)

0

(0)

0

(0)

Mali

All

 

143

(69)

65

(31)

208

1

(0)

7

(3)

7

(3)

0

(0)

11

(5)

39

(19)

New

127

(85)

23

(15)

150

1

(1)

7

(5)

6

(4)

0

(0)

4

(3)

5

(3)

Retreatment

16

(28)

42

(72)

58

0

(0)

0

(0)

1

(2)

0

(0)

7

(12)

34

(59)

Nigeria/Ibadan

All

 

31

(54)

26

(46)

57

1

(2)

1

(2)

4

(7)

0

(0)

3

(5)

17

(30)

New

11

(85)

2

(15)

13

0

(0)

1

(8)

1

(8)

0

(0)

0

(0)

0

(0)

Retreatment

20

(45)

24

(55)

44

1

(2)

0

(0)

3

(7)

0

(0)

3

(7)

17

(39)

Nigeria/Lagos

All

 

27

(22)

93

(78)

120

0

(0)

6

(5)

11

(9)

0

(0)

5

(4)

71

(59)

New

11

(40)

17

(61)

28

0

(0)

1

(4)

5

(18)

0

(0)

2

(7)

9

(32)

Retreatment

16

(18)

72

(82)

88

0

(0)

5

(6)

6

(7)

0

(0)

3

(3)

58

(66)

Unknown

0

(0)

4

(100)

4

0

(0)

0

(0)

0

(0)

0

(0)

0

(0)

4

(100)

Senegal

All

 

60

(80)

15

(20)

75

0

(0)

3

(4)

1

(1)

0

(0)

3

(4)

8

(11)

New

49

(90)

6

(11)

55

0

(0)

1

(2)

1

(2)

0

(0)

1

(2)

3

(5)

Retreatment

11

(55)

9

(45)

20

0

(0)

2

(10)

0

(0)

0

(0)

2

(10)

5

(25)

Togo

All

 

142

(67)

70

(33)

212

4

(2)

14

(7)

16

(7)

1

(0)

5

(2)

30

(14)

New

79

(84)

15

(16)

94

1

(1)

1

(1)

7

(7)

0

(0)

1

(1)

5

(5)

Retreatment

62

(55)

50

(45)

112

3

(3)

13

(12)

8

(7)

1

(1)

3

(3)

22

(20)

Unknown

1

(17)

5

(83)

6

0

(0)

0

(0)

1

(17)

0

(0)

1

(17)

3

(50)

All study sites

All

 

599

(61)

375

(39)

974

10

(1)

45

(5)

60

(6)

2

(0)

43

(4)

215

(22)

New

332

(80)

84

(20)

416

4

(1)

16

(4)

24

(6)

1

(0)

13

(3)

26

(6)

Retreatment

253

(47)

281

(53)

534

6

(1)

29

(5)

35

(7)

1

(0)

28

(5)

182

(34)

Unknown

14

(58)

10

(42)

24

0

(0)

0

(0)

1

(4)

0

(0)

2

(8)

7

(29)

  1. The overall proportion of resistance to any drug is displayed as well as a detailed description of resistant isolates and their resistant patterns, stratified by mono-resistance to rifampicin (RMP), isoniazid (INH), streptomycin (SM), ethambutol (EMB), poly-drug-resistance (PDR, resistance to a combination of any two first-line drugs except for MDR) and multi-drug-resistance (MDR, resistance to at least both RMP and INH)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us